NCT02815709已完成3 期
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Trevena Inc.
- 入组人数
- 418
- 试验地点
- 2
- 主要终点
- Number of Patients Who Respond to Study Medication at the 48-hr Numeric Pain Rating Scale (NRS) Assessment Compared to Placebo.
研究概览
简要总结
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute postoperative pain after bunionectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.
- •Experiences a pain intensity rating of moderate to severe acute pain.
- •Able to provide written informed consent before any study procedure.
排除标准
- •ASA Physical Status Classification System classification of P3 or worse.
- •Has surgical or post-surgical complications.
- •Has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •Has previously participated in another TRV130 clinical study.
研究组 & 干预措施
Treatment 1 Oliceridine
Experimental
干预措施: Oliceridine (Drug)
Treatment 2 Oliceridine
Experimental
干预措施: Oliceridine (Drug)
Treatment 3 Oliceridine
Experimental
干预措施: Oliceridine (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Morphine
Active Comparator
干预措施: Morphine (Drug)
结局指标
主要结局
Number of Patients Who Respond to Study Medication at the 48-hr Numeric Pain Rating Scale (NRS) Assessment Compared to Placebo.
时间窗: 48 hours
次要结局
- Number of Respiratory Safety Events Compared to Morphine.(48 hours)
- Odds Ratio of Patients Who Respond to Study Medication at the 48-hr NRS Assessment Compared to Morphine.(48 hours)
- Number of Patients With Treatment-related Adverse Events.(48 hours)
- Duration of Respiratory Safety Events Compared to Morphine.(48 hours)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After AbdominoplastyAcute PainNCT02820324Trevena Inc.407
已完成
4 期
Intravenous Oliceridine and Opioid-related ComplicationsMajor SurgeryNCT04979247The Cleveland Clinic204
Unknown
3 期
Phase 3 Efficacy and Safety Study of VVZ-149 Injections for Postoperative Pain Following BunionectomyPain, PostoperativeNCT04430088Vivozon, Inc.300
已完成
3 期
Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following AbdominoplastyPain, PostoperativeNCT03997838Vivozon, Inc.307
已完成
3 期
A Phase 3 Study of F14 for Management of Pain Following Total Knee ReplacementPost Operative PainNCT05603832Arthritis Innovation Corporation151